2673-2092

healthbook TIMES Oncology Hematology

Mediscience GmbH

View prefix report (10.36000)

Health Score

0 Poor

Metadata coverage

Abstract
ORCID
References
License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder
Award / grant

Affiliation & institutional identifiers

Affiliation
ROR ID

Update policy

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

1

Deposit reference lists for 225 records

Deposited references power Crossref's Cited-by links between your articles and the literature.

High impact225 DOIs
2

Attach ORCID iDs across 225 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

High impact225 DOIs
3

Add license metadata to 225 records

License metadata tells indexers and readers how each article may be reused.

High impact225 DOIs

DOIs for this ISSN

Showing the top 5 of 200 DOIs, ordered by correction priority.

# Title Missing Priority Citations
1 Advancements in Machine Learning (ML): Transforming the Futu… (10.36000/hbt.oh.2024.20.146)
Abstract References ORCID License
69.90 4
2 Rare Adverse Events of CAR T-Cell Therapy (10.36000/hbt.oh.2024.19.138)
Abstract References ORCID License
60.21 3
3 Benefits and Applications of Oncotype DX Breast Recurrence S… (10.36000/hbt.oh.2023.16.107)
Abstract References ORCID License
47.71 2
4 Comprehensive Review on PARP Inhibitors in Ovarian Cancer: A… (10.36000/hbt.oh.2023.17.120)
Abstract References ORCID License
47.71 2
5 Assessment and Treatment of Elderly Patients with Multiple M… (10.36000/hbt.oh.2024.20.151)
Abstract References ORCID License
47.71 2
6 Genomic Testing for Advanced Prostate Cancer: Ready for Prim… (10.36000/hbt.oh.2019.02.007)
Abstract References ORCID License
30.10 1
7 Critical Review of EGFR-Mutated NSCLC: What We Do and Do Not… (10.36000/hbt.oh.2020.03.012)
Abstract References ORCID License
30.10 1
8 Folate Receptor α: A New Target for an Old Enemy? (10.36000/hbt.oh.2020.05.022)
Abstract References ORCID License
30.10 1
9 Prostate Cancer Highlights from ASCO GU 2021: Cutting-Edge R… (10.36000/hbt.oh.2021.08.041)
Abstract References ORCID License
30.10 1
10 https://onco-hema.healthbooktimes.org/article/29047-mrna-vac… (10.36000/hbt.oh.2021.09.045)
Abstract References ORCID License
30.10 1
11 The Evolving Systemic Treatment for Advanced Hepatocellular… (10.36000/hbt.oh.2021.10.057)
Abstract References ORCID License
30.10 1
12 Evolving Therapeutic Strategies in Gastrointestinal Stromal… (10.36000/hbt.oh.2023.17.118)
Abstract References ORCID License
30.10 1
13 Antibody-Drug Conjugates in Ovarian Cancer: Promises and Cha… (10.36000/hbt.oh.2023.17.119)
Abstract References ORCID License
30.10 1
14 Boosting Immunity and Enhancing Wellbeing: The Transformativ… (10.36000/hbt.oh.2023.18.125)
Abstract References ORCID License
30.10 1
15 Recent Progress in Breast Cancer Treatment (10.36000/hbt.oh.2024.19.137)
Abstract References ORCID License
30.10 1
16 Endometrial Cancer: Updates in Molecular Characterization an… (10.36000/hbt.oh.2024.19.141)
Abstract References ORCID License
30.10 1
17 Rare Toxicities of CAR T-Cell Therapy: Cardiovascular, Hemat… (10.36000/hbt.oh.2024.20.147)
Abstract References ORCID License
30.10 1
18 Durvalumab Plus Chemotherapy for Advanced Biliary Tract Canc… (10.36000/hbt.oh.2024.21.157)
Abstract References ORCID License
30.10 1
19 Current Advances in the Perioperative Treatment of Muscle-In… (10.36000/hbt.oh.2025.24.184)
Abstract References ORCID License
30.10 1
20 Therapy Management of Metastatic Prostate Carcinoma in Gener… (10.36000/hbt.oh.2019.01.004)
References ORCID License
22.58 1
21 Response to Osimertinib in a Patient With Non-Small Cell Lun… (10.36000/hbt.oh.2020.03.011)
References ORCID License
22.58 1
22 Oncofertility Approach in Females With Leukemia From the Rep… (10.36000/hbt.oh.2020.04.015)
References ORCID License
22.58 1
23 Personalizing Cancer Diagnostics and Treatments in the Era o… (10.36000//hbt.oh.2021.10.055)
Abstract References ORCID License
0.00 0
24 Management of Elderly and Old Cancer Patients – Geriatric On… (10.36000//hbt.oh.2021.10.061)
Abstract References ORCID License
0.00 0
25 From New Molecular Insights to New Treatment Options in Endo… (10.36000//hbt.oh.2022.11.063)
Abstract References ORCID License
0.00 0
26 Benefits and Complications Following First-Line Treatment wi… (10.36000//hbt.oh.2022.11.064)
Abstract References ORCID License
0.00 0
27 The Evolving Treatment Landscape of AML (10.36000//hbt.oh.2022.11.065)
Abstract References ORCID License
0.00 0
28 Highlights in CAR T-Cell Therapy from ASH 2021: Potential Pr… (10.36000//hbt.oh.2022.11.066)
Abstract References ORCID License
0.00 0
29 Highlights in AL Amyloidosis from ASH 2021 (10.36000//hbt.oh.2022.11.067)
Abstract References ORCID License
0.00 0
30 Precision Oncology: Another Tower of Babel? (10.36000//hbt.oh.2022.13.081)
Abstract References ORCID License
0.00 0
31 Training the Next Generation of Physicians – Recognizing the… (10.36000/10.36000/hbt.oh.2022.14.093)
Abstract References ORCID License
0.00 0
32 The CAR T Cell Story (10.36000/hbt.oh.2019.01.001)
References ORCID License
0.00 0
33 Long-Term Sustained Disease Control With Immunotherapy in Ch… (10.36000/hbt.oh.2019.01.003)
References ORCID License
0.00 0
34 CD19-Directed CAR T Cells Treatment in a Patient With Refrac… (10.36000/hbt.oh.2019.01.005)
References ORCID License
0.00 0
35 Use of First-Line PARP Inhibitors in Ovarian Cancer (10.36000/hbt.oh.2019.02.006)
References ORCID License
0.00 0
36 Immunotherapy in Advanced Gastroesophageal Tumors: The Best… (10.36000/hbt.oh.2019.02.008)
References ORCID License
0.00 0
37 First-line treatment of ALK-positive NSCLC (10.36000/hbt.oh.2019.02.009)
References ORCID License
0.00 0
38 A Rational Sequencing of Anti-Angiogenic Agents as Second-Li… (10.36000/hbt.oh.2020.03.010)
References ORCID License
0.00 0
39 Avenues to Precision Oncology (10.36000/hbt.oh.2020.03.013)
References ORCID License
0.00 0
40 Neither Last nor Least: Integration of Early Palliative Care… (10.36000/hbt.oh.2020.04.014)
References ORCID License
0.00 0
41 Precision Oncology for Hepato-Pancreato-Biliary (HPB) Cancer… (10.36000/hbt.oh.2020.05.016)
Abstract References ORCID License
0.00 0
42 Targeting the Tumor in Colorectal Cancer – Where do we Stand… (10.36000/hbt.oh.2020.05.017)
Abstract References ORCID License
0.00 0
43 Precision Oncology in Gastro-Esophageal Adenocarcinoma (10.36000/hbt.oh.2020.05.018)
Abstract References ORCID License
0.00 0
44 Molecular Diagnostic and Precision Medicine in Non-Small Cel… (10.36000/hbt.oh.2020.05.019)
Abstract References ORCID License
0.00 0
45 Breast Cancer Treatment in the Era of Precision Medicine (10.36000/hbt.oh.2020.05.020)
Abstract References ORCID License
0.00 0
46 Precision Oncology and Gender Medicine – Moving Forward, Slo… (10.36000/hbt.oh.2020.05.21)
Abstract References ORCID License
0.00 0
47 Multiple Myeloma with a Special Focus on Precision Medicine (10.36000/hbt.oh.2020.06.023)
Abstract References ORCID License
0.00 0
48 Precision Medicine in BCR-ABL1 Negative Myeloproliferative N… (10.36000/hbt.oh.2020.06.024)
Abstract References ORCID License
0.00 0
49 Hodgkin’s Lymphoma after Autologous Stem-Cell Transplantatio… (10.36000/hbt.oh.2020.06.025)
Abstract References ORCID License
0.00 0
50 Current Standard of Care in Patients with Myelodysplastic Sy… (10.36000/hbt.oh.2020.06.026)
Abstract References ORCID License
0.00 0